AB 16B5

Drug Profile

AB 16B5

Alternative Names: 16B5; AB-16B5; AB-sCLU mAB; Anti-clusterin monoclonal antibody - Alethia Biotherapeutics

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Research Council Biotechnology Research Institute
  • Developer Alethia BioTherapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Clusterin inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Apr 2017 Adverse events, efficacy and pharmacokinetics data from the phase I trial in solid tumours presented at the 108th annual meeting of the American Association for Cancer Research (AACR-2017)
  • 21 May 2015 Alethia Biotherapeutics is planning a phase I trial in Solid tumours (Late-stage disease) in Canada (NCT02412462)
  • 01 Apr 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV) (NCT02412462)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top